LON:NCYT - Novacyt Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 570
  • Forecasted Upside: 125.70 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 252.55
▼ -0.15 (-0.06%)

This chart shows the closing price for NCYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novacyt Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NCYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NCYT

Analyst Price Target is GBX 570
▲ +125.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Novacyt in the last 3 months. The average price target is GBX 570, with a high forecast of GBX 570 and a low forecast of GBX 570. The average price target represents a 125.70% upside from the last price of GBX 252.55.

This chart shows the closing price for NCYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Novacyt.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/18/2021Numis SecuritiesReiterated RatingBuyGBX 570
6/29/2021Numis SecuritiesReiterated RatingBuyGBX 570
5/17/2021Numis SecuritiesReiterated RatingBuyGBX 570
3/11/2021Oddo BhfInitiated CoverageNeutral
3/11/2021Oddo SecuritiesInitiated CoverageNeutral
(Data available from 10/18/2016 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
9/18/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/18/2021

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Novacyt

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Lab21 Products, IT-IS International, and Primerdesign segments. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The Primerdesign segment designs, manufactures, and markets molecular Â'real-time' qPCR testing devices and reagents in the areas of infectious diseases. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves public hospitals, central laboratories, private testing, and mobile laboratories. Novacyt S.A. was incorporated in 2006 and is headquartered in Camberley, the United Kingdom.
Read More

Today's Range

Now: GBX 252.55
Low: 247.20
High: 261.26

50 Day Range

MA: GBX 326.11
Low: 252.70
High: 426.30

52 Week Range

Now: GBX 252.55
Low: 245.90
High: 1,276

Volume

258,940 shs

Average Volume

725,362 shs

Market Capitalization

£178.37 million

P/E Ratio

2.11

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Novacyt?

The following Wall Street analysts have issued stock ratings on Novacyt in the last twelve months: Numis Securities Ltd, Oddo Bhf, and Oddo Securities.
View the latest analyst ratings for NCYT.

What is the current price target for Novacyt?

1 Wall Street analysts have set twelve-month price targets for Novacyt in the last year. Their average twelve-month price target is GBX 570, suggesting a possible upside of 125.6%. Numis Securities Ltd has the highest price target set, predicting NCYT will reach GBX 570 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 570 for Novacyt in the next year.
View the latest price targets for NCYT.

What is the current consensus analyst rating for Novacyt?

Novacyt currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NCYT, but not buy more shares or sell existing shares.
View the latest ratings for NCYT.

How do I contact Novacyt's investor relations team?

The company's listed phone number is 33 1 39 46 51 04. The official website for Novacyt is www.novacyt.com.